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Summary
 
To characterize the importance of a highly conserved region of the class II 
 
b
 
 chain, we intro-
duced an amino acid substitution that is predicted to eliminate a hydrogen bond formed be-
tween the class II molecule and peptide. We expressed the mutated 
 
b
 
 chain with a wild-type 
 
a
 
chain in a murine L cell by gene transfection. The mutant class II molecule (81
 
b
 
H
 
2
 
) assembles
normally in the endoplasmic reticulum and transits the Golgi complex. When invariant chain (Ii)
is coexpressed with 81
 
b
 
H
 
2
 
, the class II–Ii complex is degraded in the endosomes. Expression of
81
 
b
 
H
 
2
 
 in the absence of Ii results in a cell surface expressed molecule that is susceptible to pro-
teolysis, a condition reversed by incubation with a peptide known to associate with 81
 
b
 
H
 
2
 
.
We propose that 81
 
b
 
H
 
2
 
 is protease sensitive because it is unable to productively associate with
most peptides, including classII–associated invariant chain peptides. This model is supported by
our data demonstrating protease sensitivity of peptide-free wild-type I-A
 
d
 
 molecules. Collec-
tively, our results suggest both that the hydrogen bonds formed between the class II molecule
and peptide are important for the integrity and stability of the complex, and that empty class II
molecules are protease sensitive and degraded in endosomes. One function of DM may be to
insure continuous groove occupancy of the class II molecule. 
Key words: major histocompatibility complex class II • peptide • hydrogen bond • invariant 
chain • proteolysis
 
O
 
ccupancy of the MHC-encoded class II molecule
plays a key role in its fate. Association of the surrogate
peptide CLIP,
 
1
 
 derived from invariant chain (Ii), with class
II molecules enhances assembly and export from the endo-
plasmic reticulum (ER) (1–6). In the absence of Ii, class II
molecules can bind other proteins in the ER via the peptide
binding pocket (7, 8), thus suggesting a drive for binding
site occupancy. In addition, when Zhong and co-workers
engineered a class II 
 
b
 
 chain to express a covalently linked,
antigenic peptide at its amino terminus, it assembled more
efficiently with 
 
a
 
 chain and egressed more quickly from the
ER than wild-type (WT) class II molecules (9). Hence,
occupancy of the class II binding site in the ER by a teth-
ered peptide promotes rapid transport of class II–peptide
complexes into the Golgi.
The association of peptide with class II molecules also
has consequences late in biosynthesis, i.e., in post-Golgi
compartments. Several groups have shown that the exoge-
nous provision of peptide increases the half-life and yield of
class II molecules in both the endosomal compartments and
at the cell surface (10–12). In addition, the work of Germain
and co-workers suggests that in the absence of peptide,
empty class II molecules aggregate in endosomes (12).
Hence, peptide plays an important role in the entire life cy-
cle of the class II molecule, from facilitating its assembly in
the ER to determining its longevity in the endosomal
compartments and at the cell surface.
Solving the three-dimensional crystal structures of both a
class I–peptide complex and a class II–peptide complex di-
rectly demonstrated that the MHC-encoded 
 
a
 
 and 
 
b
 
chains formed a groove occupied by peptide (13, 14). The
crystal structures also provided insight into exactly how the
class II molecule associates with peptide (14–18), identify-
ing both the pockets that form stable interactions with the
peptide side chains, as well as the hydrogen bonds that
form between amino acid (aa) side chains of the class II
 
1
 
Abbreviations used in this paper:
 
 aa, amino acids; CHO, Chinese hamster
ovary; CLIP, class II–associated invariant chain peptides; cys, cystatin-C;
ER, endoplasmic reticulum; GPI, glycan-phosphatidylinositol; HPAP,
human placental alkaline phosphatase; Ii, invariant chain; PK, proteinase
K; RT, room temperature; WT, wild-type.
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molecule and the main chain atoms of the peptide (Fig. 1,
 
top
 
). The majority of these hydrogen bonds involve aa’s
that are conserved in mouse and human class II molecules
(14–18).
One highly conserved region of the class II 
 
b
 
 chain lies
at the periphery of its antigen-binding pocket at residues
79–83. Amino acids 81 and 82 form hydrogen bonds to the
peptide main chain. To characterize the importance of the
histidine at position 81, we created a transfected murine fi-
broblast L cell line that expressed the mutant class II mole-
cule formed by association of a WT A
 
d
 
 
 
a
 
 chain with an A
 
d
 
b
 
 chain in which a conservative aa substitution was intro-
duced at residue 81, changing a histidine to an asparagine
(His
 
®
 
Asn) (19). The mutant A
 
d
 
 molecule lacking the po-
tential for a single hydrogen bond to the peptide main
chain will hereafter be referred to as 81m or as 81
 
b
 
H
 
2
 
.
The mutant class II 
 
b
 
 chain assembles normally with the
WT 
 
a
 
 chain in the ER. The assembled mutant class II mol-
ecule then transits the Golgi, obtains mature glycosylation,
and has a half-life comparable to that of WT A
 
d
 
 expressed in
L cells (20). However, 81
 
b
 
H
 
2
 
 does not form detectable
SDS-stable dimers, suggesting that 81
 
b
 
H
 
2
 
 does not stably
associate with peptide. In addition, 81
 
b
 
H
 
2
 
 is not detected
in the endosomes, unlike WT class II where 15% of the
steady-state pool is localized to these compartments (20).
In this paper, we characterize the fate of the mutant class
II molecule, 81
 
b
 
H
 
2
 
. Although coexpression of Ii redistrib-
utes 81
 
b
 
H
 
2
 
 to the endosomes (19), we show here that Ii
also dramatically reduces the level of 81
 
b
 
H
 
2
 
 expressed at
the cell surface and changes its fate within the cell. Upon
reaching the endosomes, 81
 
b
 
H
 
2
 
 in association with Ii is
rapidly degraded. Based on our experiments examining the
susceptibility of 81
 
b
 
H
 
2
 
 to proteases as well as its ability to
bind peptides, we hypothesize that when 81
 
b
 
H
 
2
 
 accesses
the endosomes and class II–associated invariant chain pep-
tide (CLIP) dissociates, 81
 
b
 
H
 
2
 
 is unable to productively
associate with available peptides. These empty class II mol-
ecules are then susceptible to degradation. We conclude
that peptide is key to the endosomal survival of both mu-
tant and WT class II molecules and propose that a principle
role of CLIP and DM is to insure continuous groove occu-
pancy by peptide.
 
Materials and Methods
 
Cell Lines, DNA Construct Cell Lines, and Protease Treatment.
 
Cell lines were maintained at 37
 
8
 
C and 5% CO
 
2
 
 in DMEM con-
taining 5% FCS and 5% BCS supplemented with 5 mM Hepes,
2 mM glutamine, and 1 mM nonessential amino acids (complete
medium). All media and supplements were purchased from
GIBCO BRL (Gaithersburg, MD) unless otherwise noted. The
derivation of L cell transfectants expressing 81
 
b
 
H
 
2
 
, 81
 
b
 
H
 
2
 
 Ii (e.g.,
81
 
b
 
H
 
2
 
Ii), WT, and WTIi was described previously (19, 20).
Chinese hamster ovary (CHO) cells were transfected with genes
encoding WT I-A
 
d
 
 molecules or I-A
 
d
 
 molecules that had been
modified so that they were linked to the plasma membrane by
the phospholipid linker derived from the human placental alka-
line phosphatase (HPAP) I-E
 
k
 
 construct, described by Davis and
colleagues (21). G418 (geneticin) and HAT were obtained from
GIBCO BRL. Proteinase K (PK) and trypsin were obtained from
Sigma Chemical Co. (St. Louis, MO). Trypsin-EDTA was ob-
tained from GIBCO BRL and was used directly as supplied by
the manufacturer. 100 mg of PK was resuspended in 10 ml of
DMEM and filter sterilized through a 0.45-
 
m
 
m filter right before
use. TPCK-trypsin was obtained from Sigma Chemical Co. and
prepared in the same way as PK at a concentration of 50 mg/ml.
The final solution of trypsin was neutralized with 1 N NaOH. To
treat the L cells with proteases, we first adapted them to petri
dishes to grow them nonadherently. The cells were pelleted from
culture media, rinsed once with DMEM-Hepes, and resuspended
in 1–2 ml of the protease. CHO cells were treated similarly, but
before protease treatment they were maintained adherent in tissue
culture dishes, and harvested immediately before enzyme treat-
ment by brief incubation with EDTA (Versene; GIBCO BRL).
After treatment for 0.5 h at room temperature (RT) for PK or 10
min at 37
 
8
 
C for trypsin, 1 ml of calf serum was added, and the
cells were pelleted, washed with complete medium, and analyzed
by flow cytometry. In experiments where trypsin-EDTA was
used, enzyme treatment was for 0.5 h at RT. Ammonium chlo-
ride was obtained from Sigma Chemical Co. and used at a final
concentration of 20 mM. The protease inhibitor, Z-phe-ala was
obtained from P. Morton (Searle, Chesterfield, MO) and used at
a final concentration of 10 
 
m
 
M.
 
Monoclonal Antibodies.
 
The hybridomas producing mAb reac-
tive with I-A
 
d
 
 (MKD6, M5/114) and with class I K
 
k
 
 (16-1-11N)
were obtained from American Type Culture Collection (Rockville,
MD). The specificity of the anti–class II mAbs has been described
previously (22). ID4B is a rat mAb that recognizes murine LAMP-1
and was provided by Dr. Thomas August (Dept. of Pharmacology
and Molecular Sciences, Johns Hopkins, Baltimore, MD). The rab-
bit anti–I-A
 
d
 
 
 
b
 
 chain cytoplasmic tail peptide was produced by HTI
Bioproducts, Inc. (Ramona, CA) using the peptide AB described
below. The rat mAb In-1, which recognizes the amino terminus of
Ii was provided to us by Jim Miller (University of Chicago, Chi-
cago, IL). Its characterization is described in reference 23.
 
Peptides.
 
The AB and cystatin-C (cys) peptides were synthe-
sized by Dr. Giri Reddy of the University of Chicago Amino
Acid and Protein Core Labs., Chicago, IL. The cys derived pep-
tide is DAYHSRAIQVVRARKQ (aa 40–55), and the AB pep-
tide is CQKGPRGPPPAGLLQ, which corresponds to the cyto-
plasmic tail of I-A 
 
b
 
. The concentration of cys derived peptide
used in the experiments (20.75 
 
m
 
M; 43.75 
 
m
 
g/ml) was deter-
mined to be the optimal concentration of peptide that increased
surface expression of 81
 
b
 
H
 
2
 
 but did not increase staining with
the fluoresceinated, second step GAM reagent.
 
Flow Cytometry Analysis.
 
MHC cell surface expression was
measured by staining with mAb followed by a secondary staining
reagent FITC-labeled goat anti–mouse Ig (FITC-GAM) (Cappel
Laboratories, Cochranville, PA) as described previously (24). The
samples were analyzed on a FACScan
 
Ò
 
 cytofluorometer (Becton
Dickinson, Mountain View, CA).
 
Metabolic Labeling, Immunoprecipitation, and SDS-PAGE.
 
For
the pulse-chase experiments, 5 
 
3
 
 10
 
5
 
 cells per time point were
plated out the night before in complete media in 60-mm tissue
culture dishes. The next day, the cells were prelabeled for 1.5 h in
leucine-free DMEM supplemented with 5% dialyzed FCS. The
cells were then labeled in the same medium containing 300–350
 
m
 
Ci/ml of [
 
3
 
H]leucine (Amersham Corp., Arlington Heights,
IL), at 37
 
8
 
C, 5% CO
 
2
 
 for 30–45 min. The pulse plates were
washed once in cold complete media and lysed in 0.5% NP-40
lysis buffer with the protease inhibitors TPCK (50 
 
m
 
g/ml), PMSF 
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(200 
 
m
 
g/ml), leupeptin (0.5 
 
m
 
g/ml) (Boehringer Mannheim Bio-
chemicals, Indianapolis, IN), and 20 mM iodo-acetamide. The
chase point plates were washed and incubated in prewarmed me-
dium containing a twofold excess of unlabeled leucine for the in-
dicated chase times. The radiolabeled cells were lysed on the
dishes on ice. Postnuclear supernatants were precleared for 1 h
with 60 
 
m
 
l of packed PAS (Pharmacia Biotech AB, Uppsala,
Sweden) for the mouse mAbs and rabbit antisera or with PGS
(Pharmacia Biotech AB) for the rat mAbs. The lysates were then
incubated with PAS or PGS prebound with the appropriate anti-
body for at least 2 h. The immunoprecipitated material was
washed three times in lysis buffer, resuspended in sample buffer
counting 2% 2-ME, boiled, and analyzed by SDS-10% PAGE.
Gels were treated with En
 
3
 
Hance (NEN Research Products,
Boston, MA) or Fluor-Hance (Research Products International,
Mount Prospect, IL) and subjected to autoradiography at 
 
2
 
80
 
8
 
C.
The overnight labeling was done in 300 
 
m
 
Ci/ml of leucine in 3 ml
of leucine-free media (ICN Biomedicals, Inc., Costa Mesa, CA).
 
CLIP Analysis.
 
CLIP analysis was performed essentially as
described above except for the following changes. The cells were
labeled for 0.5 h in 250 
 
m
 
Ci/ml of [
 
35
 
S]methionine (Amersham
Corp.) in methionine-free DMEM. The immunoprecipitated pro-
teins were resolved on a 12.5% SDS polyacrylamide gel which was
run until the dye front was 
 
z
 
2 inches from the bottom of the glass
plates. The gels were treated sequentially, for 20 min each, with fix-
ative (30% methanol, 10% acetic acid), water, and then Fluor-Hance
(Research Products International) before drying at 75
 
8
 
C for 2 h.
 
Cell Surface Biotinylation and Western Blot Analysis.
 
The cells
were plated the night before at a density of 5 
 
3
 
 10
 
5
 
/2 ml on 60-
mm tissue culture dishes. The next day the plates were rinsed six
times with cold PBS-CM (PBS with 1 
 
mM CaCl and 250 mM
MgCl) and then incubated 30 min with 1.5 mg/ml NHS-SS-bio-
tin (Pierce Chemical Co., Rockford, IL) in PBS-CM on ice with
gentle rocking. The biotinylation reaction was stopped by wash-
ing the cells six times with 50 mM glycine in PBS-CM. Cells
were lysed on the dishes on ice in lysis buffer containing 0.5%
CHAPS with the protease inhibitors and iodo-acetamide as de-
scribed above. The postnuclear supernatants were precleared with
PAS as described above and then sequentially immunoprecipi-
tated with PAS prebound to 16-1-11N, followed by immuno-
precipitation with PAS prebound to the rabbit antiserum (10 ml/
sample). The immunoprecipitates were washed two to three
times with lysis buffer, resuspended, boiled in sample buffer lack-
ing 2-ME, and resolved by SDS-PAGE. The proteins were trans-
ferred on to nitrocellulose membranes at 250 milliamps for 2 h.
The membranes were blocked with 3% BSA in a buffer com-
posed of 0.5% Tween 20, 1 M d-glucose, and 10% glycerol. The
membranes were then incubated for 1 h in a 50-ml solution con-
taining 10% of the solution described above plus 15 ml of strepta-
vidin conjugated to HRP (GIBCO BRL) and then washed ex-
tensively with Tris-buffered saline containing 0.05% Tween 20
(TBST) and developed by chemiluminescence using ECL (Amer-
sham Corp.). Western blot analysis of the p12 fragment was car-
ried out as described elsewhere (25). In brief, the nitrocellulose
containing the immobilized proteins was blocked for 1 h in water
containing 5% powdered nonfat milk, 0.1% sodium azide, and
0.028% antifoam (Sigma Chemical Co.). The membranes were
then probed sequentially for class II and Ii with M5114 and In-1,
respectively, for at least 3 h. A 1:5,000 dilution of a species-specific
secondary antibody coupled to horseradish peroxidase was added to
the blot for 1 h before extensive washes in TBST. The blots were
then developed using chemiluminescence using LumiGLOÔ
(Kirkegaard & Perry Laboratories, Inc., Gaithersburg, MD).
Results
Ii Coexpression Alters Fate of 81bH2. Although the His®
Asn substitution at position 81 of the class II b chain is
considered a conservative aa substitution, this mutation is
predicted to disrupt a hydrogen bond between class II and
the peptide backbone (Fig. 1). When the gene encoding
the substituted b chain is introduced into L cells, the mu-
tated b chain assembles with WT Ad a chain and is ex-
pressed at the cell surface at levels comparable to WT (19).
Surprisingly, coexpression of Ii causes a dramatic decrease
in the amount of 81bH2 expressed at the cell surface (Fig.
2 A, right). These data are in contrast to studies done in our
Figure 1. Model of class II–peptide interactions. (Top) Hydrogen bonds
formed between the I-Ad molecule and the ovalbumin peptide backbone
(18). The a chain is shown in blue and the b chain is shown in red. The
histidine at aa 81 of the b chain is shown in yellow with the nitrogen at-
oms colored blue. Oxygen atoms are shown in red and the peptide bonds
and carbon atoms are colored gray. The hydrogen bonds are indicated by
the dashed lines. (Bottom) Close-up view of the hydrogen bond formed
between the histidine at position 81 of the b chain and peptide backbone
(distance, z2.7 Å). Asparagine was substituted for histidine and a com-
mon rotamer conformation was chosen to overlap the histidine side
chain. In this conformation the distance from the peptide carbonyl to the
asparagine nitrogen is 4.2 Å. The program O (50) was used to model the
histidine to asparagine mutation and to select a common rotamer for as-
paragine. The figure was made with the program MOLSCRIPT (51).2142 Class II Molecule Degraded in Endosomes
lab and others (2, 4) where coexpression of Ii with WT
class II molecules facilitates transport and cell surface ex-
pression of class II.
The low levels of class II surface expression observed on
81bH2Ii-expressing cells are not caused by the loss of class
II gene expression, but rather correlate with rapid degrada-
tion (Fig. 2 B). At time 0, a, Ii, and b chains are present.
By 2 h, the b chain has increased in size, as has the a chain,
indicating that the abIi complex has left the ER and has
undergone additional glycosylation in the Golgi complex.
At 3 h, there is noticeable attrition of the entire abIi com-
plex, which is nearly gone by the 4-h chase point. We con-
clude that the deficiency in cell surface class II expression
on 81bH2Ii-expressing cells cannot be accounted for by
low class II protein synthesis; rather, its loss occurs rela-
tively late in its biogenesis.
We compared the fate of 81bH2Ii with that of 81bH2,
WT, and WTIi in a pulse–chase experiment (Fig. 3). All of
the cell lines have similar maturation kinetics early in the
pulse–chase experiment where mature a and b chains are
present after 2 h. Cells expressing WT class II with Ii lose Ii
between 2 and 3 h, indicating that the class II–Ii complex has
accessed the endosomal compartments. A strikingly different
pattern is observed in cells expressing 81bH2Ii (Fig. 3, D and
B). In Fig. 3 B, the mature 81bH2Ii complex begins to dis-
appear at 3 h and is undetectable by 4 h. In contrast, mature
class II molecules persist in cells expressing 81bH2, WT, or
WT class II and Ii after 5 h of chase (Fig. 3, A, C, and D). We
conclude that the loss of 81bH2 in the presence of Ii is
unique to the mutant class II molecule, as it is not seen in cells
expressing 81bH2, WT class II, or WT class II and Ii.
Loss of the 81bH2Ii Complex Occurs in the Endosomes.
Because degradation of 81bH2 occurs late in biosynthesis
after addition of N-linked glycans in the Golgi and because
Figure 2. Coexpression of Ii results in loss of 81bH2 expression at the
cell surface. (A) Class II surface expression on stably transfected L cells ex-
pressing 81bH2 ( left) and 81bH2 supertransfected with the murine Ii
(right) was determined using mAb MKD6. Background staining detected
with the goat anti–mouse Ig conjugated to FITC (GAM) is shown as a
dashed line. (B) [3H]Leucine pulse-chase experiment of 81bH2 Ii shows
synthesis of the a, b, and Ii proteins. The cells were pulsed for 45 min (0)
followed by chase times of 2, 3, 4, 6.5, and 8 h. The cells were lysed in
0.5% NP-40 lysis buffer and immunoprecipitated sequentially with a rat
mAb recognizing LAMP-1, ID4B (I), as negative control, followed by a
rat anti–murine class II b chain, M5114 (M5). Location of the a, b, and Ii
chains are shown on the left.
Figure 3. The effect of Ii on 81bH2 is a late event in biosynthesis and
specific for 81bH2. L cells expressing 81bH2 (A), 81bH2Ii (B), WT (C),
and WTIi (D) were labeled with [3H]leucine for 30 min (0) and chased
for 1, 2, 3, 4, and 5 h. The lysates were sequentially immunoprecipitated
with ID4B (I) followed by M5114 (M5). At later time points, the class II
molecules transit the Golgi complex to attain mature glycosylation (am).2143 Ceman et al.
our previous intracellular staining data indicates that 81bH2Ii
accesses the endosomes (19), we hypothesized that the loss
of class II molecules occurs when the 81bH2Ii complex
reaches the endosomes. To test this, we used the weak
base, NH4Cl, to raise the pH of the endosomal compart-
ments. In addition, because sulfhydryl proteases have been
implicated in Ii degradation (26–32), we tested the effects
of a sulfhydryl protease inhibitor, Z-phe-ala, on 81bH2Ii.
Cells expressing 81bH2Ii were biosynthetically labeled
overnight in the presence or absence of either NH4Cl or
Z-phe-ala, and class II immunoprecipitates were prepared.
In Fig. 4 A, the short exposure clearly shows that the
81bH2Ii complex is preserved by NH4Cl treatment. The
same experiment (Fig. 4 A; right) shows that mature class II
molecules in 81bH2Ii-expressing cells can also be pre-
served by a sulfhydryl protease inhibitor. Our results
suggest that when 81bH2 has been transported with Ii into
the endocytic compartments, the complex is degraded by
endosomal proteases.
In Fig. 4 B, we compared the fate of 81bH2Ii with that
of WTIi in the presence or absence of NH4Cl. Ammonium
chloride treatment profoundly preserved Ii in both cell
lines, indicating successful neutralization of the endosomal
compartment. In addition, the amounts of mature a and b
chains are greatly increased in 81bH2Ii in the presence of
NH4Cl. We also observed some preservation of WT class II
molecules by NH4Cl. We conclude that the entire 81bH2Ii
complex is degraded, whereas only a small amount of WTIi
is degraded in the endocytic compartments upon proteoly-
sis and release of Ii.
Finally, to show that the class II–Ii complexes in cells ex-
pressing either WTIi or 81bH2Ii access the same endoso-
mal environment, we assayed for the Ii-derived p12 frag-
ment in association with class II (Fig. 4 C, p12) (33, 34).
This 12 kD degradation intermediate is derived from the
amino terminus of Ii (aa 1z102) and contains the transmem-
brane and CLIP region. Fig. 4 C shows that when similar
amounts of class II are immunoprecipitated from 81bH2Ii
and WTIi, comparable amounts of p12 are present. This
result suggests that the pool of p12-associated class II mole-
cules is the same in cells expressing either WTIi or 81bH2Ii.
Taken together, the data in Fig. 4 suggest that the class II
attrition observed in 81bH2Ii occurs endosomally but at a
point after the Ii-p12–81bH2 complex is generated.
Incubation with Peptide Protects 81bH2 from Proteolysis and
Increases the Amount of 81bH2 at the Cell Surface. Based on
Figs. 1–4, we concluded that when the 81bH2Ii complex
reaches the endocytic compartments, it is degraded. To ex-
plain why 81bH2 in association with Ii is susceptible to en-
dosomal degradation, we hypothesized that after Ii is re-
moved, 81bH2 is unable to productively bind peptides
available in the endocytic compartment. In support of this
hypothesis, we showed earlier that 81bH2 was unable to
form SDS-stable dimers (20). In addition, when we com-
pared the peptide binding capacity of the 81bH2 molecule
to the WT Ad molecule in an in vitro translation system,
we found that 81bH2 binds very poorly to most peptides.
An exception was found, however, in a cys derived peptide
(aa 40–55), which did bind 81bH2 (Wolf Bryant, P., H.
Ploegh, and A.J. Sant, manuscript in preparation). This same
cys derived peptide was one of the five predominant peptides
eluted from I-Ad molecules purified from A20 cells (35).
To test whether the 81bH2 molecule is inherently more
protease sensitive than WT class II molecules, we treated
Figure 4. The 81bH2Ii com-
plex is degraded in the endocytic
pathway. (A) 81bH2Ii was la-
beled in [3H]leucine overnight
in the absence (2) or presence
(1) of NH4Cl or the sulfhydryl
protease inhibitor, Z-phe-ala
(PI). The cells were immunopre-
cipitated sequentially with a mAb
recognizing class I (16-1-11) (bot-
tom) and then with M5114, a
mAb that recognizes the class II b
chain. This experiment is shown
as two exposures of the autora-
diograph: a 2-d exposure on the
left and a 7-d exposure on the
right. Mature a is indicated as
am; Ii and b chain are also
shown. (B) Cells expressing ei-
ther 81bH2 or WTIi were la-
beled overnight with [3H]leu-
cine in the absence (2) or
presence (1) of NH4Cl. Ii is pre-
served by NH4Cl in both cells but mature a chain is profoundly rescued in 81bH2Ii. The b chain in 81bH2Ii migrates as a smaller size than WT because
of the aa substitution at position 81. (C) 81bH2Ii and WTIi-expressing cells were lysed and immunoprecipitated with the rabbit antisera that recognizes
the cytosolic tail of the class II b chain. The proteins were resolved on a 12.5% gel, transferred to nitrocellulose, and probed first for class II b chain with
M5114 (top) and then for the amino terminus of Ii, with the rat mAb, In-1 (bottom). Immature b chain (i) in 81bH2-expressing cells is indicated by the
bottom of the bracket; mature b (m) in 81bH2Ii and WTIi-expressing cells is indicated by the top of the bracket. The p31 form of Ii is also noted by the
arrow.2144 Class II Molecule Degraded in Endosomes
intact cells with either the broadly reactive protease, PK or
with a more restricted enzyme, trypsin, which cleaves after
arginines and lysines (Fig. 5). Treatment with PK reduces
surface 81bH2 class II expression approximately twofold as
detected by the monoclonal antibody MKD6 (Fig. 5 A,
panel 1), but had no effect on WT expression (Fig. 5 A,
panel 3). Treatment of 81bH2 and WT Ad-expressing cells
with trypsin gave a similar result (Fig. 5 A, panels 5 and 7).
These experiments support our hypothesis that the 81bH2
molecule is protease sensitive compared with WT. Our
data are in contrast to the inherent protease resistance of
the class II molecule demonstrated by a number of groups
in the early studies of Ii association with class II (36–39).
These workers showed that protease treatment of class II–Ii
complexes to release Ii left the class II molecules intact.
One possible explanation for the observed protease sensi-
tivity of 81bH2 compared with WT, which we proposed
earlier, is that 81bH2 fails to acquire peptide, leading to
enhanced protease sensitivity. We hypothesize that empty
class II molecules are protease sensitive.
To determine if 81bH2 is protease sensitive because it is
empty, we asked whether peptide loading could protect
81bH2 from proteolysis. L cells expressing 81bH2 were
incubated overnight with the cys derived peptide and then
treated with proteases. Strikingly, addition of cys peptide to
81bH2-expressing cells not only protected the cells from
protease treatment (Fig. 5 A, panels 2 and 6), but also in-
creased the amount of surface 81bH2 expression (Fig. 5 B).
Fig. 5 B, panel 1 shows that incubation of 81bH2 with cys
peptide increases the cell surface expression of 81bH2
nearly fourfold, increasing the mean channel fluorescence
from 130 to 530. This increase in surface expression of
81bH2 after culture with peptide was detected by a panel
of different mAbs (data not shown) indicating an overall in-
crease in cell surface class II expression. In contrast, WT
class II expression is increased only 1.3-fold by incubation
with cys peptide (Fig. 5 B, panel 2). These data support our
model that the primary mechanism underlying the protease
sensitivity of 81bH2 is its underoccupancy by peptide. Be-
cause exogenous addition of a peptide able to bind 81bH2,
i.e., cys, confers protease resistance, we conclude that the
81bH2 molecule is protease sensitive when it is underoc-
cupied by peptide.
To show that the increase in cell surface 81bH2 expres-
sion by peptide treatment is due to an increase in the yield
of class II molecules rather than the restoration of mAb
epitopes, we used a biochemical assay that did not rely on
reactivity with mAbs. Cell surface molecules were biotiny-
lated after three different culture conditions: cells express-
ing 81bH2 incubated alone, with irrelevant peptide, AB,
or with cys derived peptide. Immunoprecipitation with an
anti–class I mAb shows that equal numbers of cells were bi-
otinylated (Fig. 6 A). Class II molecules were isolated from
the same lysates with a rabbit antiserum reactive with the
cytoplasmic tail of the I-A class II b chain. When we com-
pare 81bH2 molecules on cells incubated alone (or with a
control peptide) with those incubated with cys peptide, the
amount of recovered 81bH2 ab dimers increases approxi-
mately three- to fourfold in the presence of cys peptide.
We conclude that the increase in 81bH2 detected both by
several different mAbs (Fig. 5 and data not shown) and by
cell surface biotinylation is not due simply to a subtle con-
formational change, but rather reflects an increase in the
amount of 81bH2 expressed at the cell surface.
81bH2Ii Does Not Accumulate CLIP. The rapid degra-
dation of 81bH2Ii complexes in the endosomes predicts
that either Ii digestion products such as CLIP do not re-
Figure 5. Protease sensitivity of 81bH2. (A) 81bH2 or WT Ad-express-
ing cells were incubated overnight with or without cys derived peptide
and then treated with either PK (panels 1–4) or trypsin (TRP; panels 5–8).
(Panel 1) 81bH2-expressing cells stained with the second step goat anti–
mouse FITC reagent alone (shaded histogram) or with the mAb, MKD6,
which recognizes the murine Ad class II molecule (solid line). After PK
treatment, the mean channel fluorescence of 81bH2 is reduced from 130
to 70 (dashed line). The MKD6 staining of cells after protease treatment is
shown as a dashed line; staining after mock treatment is shown as a solid
line. (Panel 2) 81bH2-expressing cells incubated overnight with cys de-
rived peptide and then treated with or without PK. (Panel 3) WT Ad-
expressing cells stained with MKD6 after treatment with or without PK.
(Panel 4) WT Ad-expressing cells incubated overnight with cys peptide
and then treated with or without PK. A subpopulation of the WT cells
have lost expression of the Ad transgenes and therefore do not stain with
the MKD6 mAb. These cells are overlapping with the GAM FITC con-
trol (shaded histogram). Panels 5–8 show the MKD6 staining of 81bH2 or
WT Ad-expressing cells incubated alone or with the cys peptide and then
mock-treated (solid line) or treated with trypsin (dashed line). MKD6 stain-
ing of 81bH2 expressing cells was reduced from a mean channel fluores-
cence of 130 to 76 by trypsin treatment (panel 5). (B) Peptide. Panel 1
shows the MKD6 staining of 81bH2 incubated alone (solid line) or with
cys peptide (dashed line). Panel 2 shows the MKD6 staining of WT Ad-
expressing cells incubated alone (solid line) or with the cys peptide (dashed
line). Staining of the cells with only the second step GAM FITC reagent is
shown as a shaded histogram on the left.2145 Ceman et al.
main associated with 81bH2 or that CLIP binding does not
confer protease resistance to 81bH2. To explore the first
possibility, we isolated class II molecules from WTIi and
81bH2Ii expressing cells in a pulse–chase experiment and
looked for the appearance of the p12 fragment and CLIP
(Fig. 7). After 2 h of chase, abundant levels of p12 are
found associated with class II molecules in both WTIi and
81bH2Ii-expressing cells. After 3 h of chase, we can detect
CLIP ahead of the dye front in cells expressing WTIi:
however, there is no CLIP found associated with class II at
any time points in 81bH2Ii-expressing cells. Since we can-
not detect CLIP associated with 81bH2 either in a pulse–
chase (Fig. 7) or in a continuous label (data not shown), we
conclude that loss of the hydrogen bond at His 81 causes
CLIP to rapidly dissociate from 81bH2. Exogenous addi-
tion of either human or murine CLIP peptides to 81bH2-
expressing cells does not increase cell surface class II expres-
sion (data not shown). These data are consistent with our
in vitro data indicating a failure of this molecule to stably
associate with CLIP. Thus, we conclude that when 81bH2
reaches the endocytic pathway in association with Ii, the Ii
molecule is removed by proteolysis, leaving a p12–class II
complex. When this complex is further processed to CLIP–
class II, CLIP rapidly dissociates, and the empty 81bH2
molecule is degraded.
Empty WT Class II Molecules Are Protease Sensitive.
One issue raised by our preceding studies was whether the
protease sensitivity of 81bH2 was due exclusively to its un-
deroccupancy by peptide. The finding that peptide occu-
pancy by a high affinity peptide confers protease resistance
argues in favor of this conclusion. However, we wished to
evaluate the protease sensitivity of WT I-Ad molecules to
be able to generalize the conclusions we made. Empty sol-
uble class II molecules have been shown by other workers
to aggregate when they are in solution. This behavior com-
plicates attempts to assess their protease sensitivity. Thus,
we adopted an alternate strategy to examine empty WT Ad
molecules. We constructed class II I-Ad molecules that
would be tethered to the cell surface by glycan-phosphati-
dylinositol (GPI) linkage, contributed by the carboxy-
terminal segment of the GPI-linked dimer HPAP. Davis and
co-workers (21) have characterized I-Ek molecules con-
structed in such a way and conclude that these molecules
exist free of peptide at the cell surface. Recombinant I-Ad–
GPI-linked dimers were engineered from I-Ek–HPAP by
PCR and introduced into CHO cells. These molecules are
released from the cell surface by phospholipase treatment.
They do not allow presentation of antigen, but do present
peptide (data not shown). Thus, we conclude that like their
I-E counterparts, GPI-linked I-Ad molecules exist at the
cell surface primarily in a form devoid of peptide.
When tested for their protease sensitivity (Fig. 8), GPI-
linked I-Ad molecules were found to be sensitive to trypsin
treatment (Fig. 8, C), a property protected by prebinding
of peptide during overnight incubation (Fig. 8, D). Their
protease sensitivity is comparable to 81bH2 (Fig. 8, B).
Figure 6. Incubation with cys
peptide increases the yield of
81bH2 class II molecules at the
cell surface. 81bH2 incubated
alone or with AB peptide or cys
peptide were cell surface biotin-
ylated, lysed, and then immu-
noprecipitated sequentially with
an anti–class I reagent (A) fol-
lowed by a rabbit antisera raised
against the cytosolic tail of class
II I-Ad b chain (B). The a and b
chains are indicated by the ar-
rows. The Western blot was de-
veloped with streptavidin-HRP.
Figure 7. 81bH2Ii does not accumulate CLIP. Using a protocol adapted
from reference 40, L cell transfectants expressing WT Ad and Ii (top) or
81bH2Ii were pulsed for 30 min with [35S]methionine and then chased
for 2, 3, 4, or 5 h. The cells were lysed and immunoprecipitated sequen-
tially with ID4B followed by M5114. The proteins were resolved on a
12.5% polyacrylamide, reducing SDS gel that was run until the dye front
was 2 inches from the bottom. The class II a and b chains and Ii are indi-
cated on the left. CLIP runs just ahead of the dye front, both of which are
indicated by arrows, as is the p12 fragment (right).2146 Class II Molecule Degraded in Endosomes
WT I-Ad with intact transmembrane segments expressed in
CHO cells that presumably access peptide en route to the
cell surface are not protease sensitive (Fig. 8, A). We con-
clude from these studies that peptide occupancy by class II
is an essential feature to its well-known protease resistance.
Discussion
In this paper, we provide evidence that a class II mole-
cule with a compromised ability to bind peptides is suscep-
tible to proteolysis. A number of observations support this
model. First, we observed that 81bH2 in association with
Ii is degraded in the endosomes. Then, we showed that the
81bH2 molecule itself is protease sensitive and that addi-
tion of a cys derived peptide restores the protease-resistant
character observed with WT Ad. These observations led us
to propose that 81bH2 is protease sensitive because it is
empty. In support, earlier work in our lab showed that
81bH2 was unable to form SDS-stable dimers, suggesting
an inability to productively associate with peptide (20) and
our more recent work showing that 81bH2 displays greatly
enhanced dissociation rates from peptides (McFarland, B.,
C. Beeson, and A.J. Sant, manuscript in preparation).
An important question raised by these studies is why
changing a histidine to an asparagine at position 81 affects
the ability of the class II molecule to associate with peptide.
The histidine at position 81 of the b chain forms a hydro-
gen bond to the main chain of bound peptides (Fig. 1, top).
This hydrogen bond is observed in three human MHC
class II structures (14–16) and in the structures of murine
MHC class II molecules (17, 18). Although in principle, as-
paragine also has a nitrogen that could form a similar hy-
drogen bond, the side chain of asparagine is predicted to be
too short to reach the peptide backbone. All of the com-
monly observed rotamers of asparagine were compared to
histidine in the modeling of the mutant. The asparagine
rotamer with a similar orientation to the histidine was cho-
sen to show that the shorter asparagine side chain cannot
form a hydrogen bond with peptides without a large reori-
entation of the MHC alpha helix (Fig. 1, bottom). Our
modeling shows that the asparagine would be too far from
the peptide (z4.2 Å) to form a strong hydrogen bond. The
simplest explanation for the structural consequences of the
histidine to asparagine mutation is the loss of a specific pep-
tide, class II hydrogen bond. The absence of this hydrogen
bond may destabilize the binding of many peptides. Addi-
tionally, the hydrogen bond formed at position 81 may be
an important first step for initiating peptide binding to the
class II molecule, acting to position or dock the peptide be-
fore stable binding to the class II molecule occurs.
Additional data from both our lab and another lab sup-
port our conclusion that the hydrogen bonds between the
class II molecule and peptide are important for the overall
stability and integrity of the class II–peptide complex.
Glimcher and co-workers demonstrated the importance of
the aa’s at the periphery of the class II peptide binding
pocket for class II surface expression (41). They described a
mutagenized murine B lymphoma that had lost cell surface
Ad expression. They cloned and sequenced both the a and
b chain genes and found only a single aa substitution at res-
idue 82, changing an asparagine to a serine in the class II b
chain. This single aa substitution resulted in a class II mole-
cule (82m) which associated with Ii but was unable to ac-
cess the cell surface, i.e., it was retained intracellularly. Us-
ing an L cell transfection system, we also found that
coexpression of Ii reduces 82m expression at the cell sur-
face (data not shown). In addition, 82m expressed at the
cell surface in the absence of Ii is even more protease sensi-
tive than 81bH2 (data not shown). Our preliminary data
also suggest very rapid endosomal degradation of 82m
when it is expressed in association with Ii. Fig. 1 shows that
the aa at position 82 of the b chain forms two hydrogen
bonds with the peptide backbone. The Asn®Ser substitu-
tion at position 82 is predicted to eliminate both hydrogen
bonds. Such a molecule may be even more impaired in its
ability to bind or remain stably associated with peptide,
which might explain why 82m is even more protease sensi-
tive than 81bH2.
The importance of these hydrogen bonds between con-
served MHC residues and main chain atoms of the peptide
has been examined for a class I–peptide complex. By sub-
stituting methyl groups for charged aa’s in the peptide,
Bouvier and Wiley showed that more energy was contrib-
uted by the hydrogen bonds than by the anchor residues of
the peptide, suggesting that the hydrogen bonds play an
important role in the stability of the complex (42). In
agreement with this work, Hill and co-workers demon-
Figure 8. Empty WT class II molecules are protease sensitive. Genes en-
coding WT I-Ad (A) or a recombinant I-Ad molecule with the carboxy-
terminal segments derived from the GPI-linked protein HPAP (C and D)
were transfected into CHO cells. Cells were either cultured normally
overnight (C) or cultured overnight with cys (D) peptide as described in
Materials and Methods. Cells were harvested from culture and either left
untreated (filled profiles) or treated for 0.5 h at RT with trypsin-EDTA
(gray lines). Shown are the flow cytometry profiles of cells stained with the
I-Ad specific antibody MKD6. Dotted lines represent background stain-
ing. L cells expressing 81bH2 similarly treated are shown for comparison (B).2147 Ceman et al.
strated that a significant amount of free energy of binding
arises from the hydrogen bonds formed between the class II
binding site and the amide bonds of the ligand (43). In Fig.
1, aa’s 53, 62, 68, 69, and 76 of the class II a chain are
shown to form hydrogen bonds with the peptide back-
bone. Peccoud and co-workers substituted alanine at each
of these positions in a class II Ak molecule and found that
the ability to present peptides to a number of T cell hybri-
domas was detectable, although impaired. The most strik-
ing loss was observed when aa 62 was substituted (44). This
work supports the idea that the hydrogen bonds formed
between the class II molecule and peptide are very impor-
tant and that some hydrogen bonds may be particularly
critical for formation of stable peptide–class II complexes.
Our results showing the profound effects that follow
from the loss in potential for a single hydrogen bond be-
tween peptide and MHC class II molecules are particularly
interesting in light of the recent successful crystallization of
the I-Ad molecule bound to antigenic peptides (18). The
structure obtained shows that I-Ad achieves stable peptide
binding with minimal pocket interactions between the class
II molecule and the R groups of the peptide. The pockets
within the binding groove of I-Ad appear to be either
empty (P1 and P9) or only partially filled (P4). Thus, strong
pocket interactions are not essential for stable peptide inter-
actions to the class II molecules. In contrast, our results
suggest that loss in potential for a single hydrogen bond can
profoundly diminish the capacity of class II molecules to
acquire peptide. It is not yet clear if the contribution of hy-
drogen bonds will be similarly great for those MHC class II
peptide interactions that are characterized by strong pocket
interactions. We are currently examining this issue.
Although the histidine at position 81 is highly conserved,
there are some b chains which do not have a histidine at
residue 81: H-2 Abu (I-Au) and HLA DRw53. Both have a
tyrosine at position 81, suggesting that the histidine is not
required for a viable class II molecule. In describing the as-
sociation of I-Au and peptide, McConnell and Lee pro-
posed that the tyrosine substitution at 81 would either de-
lete the hydrogen bond or force a substantial shift in the
peptide backbone around the P1 pocket (45). Based on our
model that residue 81 is key for stable peptide association
with class II, one might predict that class II molecules with
a tyrosine at position 81 have evolved compensatory mech-
anisms for stable association with peptide. In support of this
hypothesis, there are aa substitutions found at positions in
the I-Au molecule that are not present in other known I-A
alleles.
Alternatively, it is interesting to consider the possibility
that a higher proportion of I-Au molecules may be empty.
It is well documented that I-Au has a low affinity for the
immunodominant epitope of myelin basic protein, Ac1-9,
which is encephalitogenic in H-2u mice (46–48). The low
affinity of I-Au for Ac1-9 is thought to contribute to disease
onset because autoreactive T cells escape self-tolerance in
the thymus. One might predict that substituting a histidine
at position 81 of I-Au would result in a higher affinity for
Ac1-9, and perhaps other peptides that interact with this
class II molecule.
In conclusion, we describe here a class II molecule,
81bH2, that is unable to remain associated with peptide
because a hydrogen bond has been altered. When 81bH2Ii
complexes access the endosomes in the presence of Ii, they
are degraded—presumably because the CLIP peptide im-
mediately dissociates after removal of Ii and no other self-
peptides are able to bind 81bH2. From our data, as well as
the work of others (10–12), we propose that empty class II
molecules in the endocytic pathway are degraded. For this
reason, the cell has two chaperones to orchestrate continu-
ous groove occupancy of the class II molecule, Ii and DM.
Ii directs the class II–Ii complex to the late endosomal
compartments via the strong sorting signal in its tail. Under
the acidic, proteolytic conditions of the endosomes, Ii is
degraded whereas the class II molecule bound by CLIP is
protected. At this point, the second chaperone, DM, facili-
tates the exchange of CLIP for antigenic peptides. How-
ever, there are some class II molecules on which CLIP has
a very fast off-rate, specifically I-Ak, I-Ed, and I-Ek (49).
The existence and survival of such molecules suggest that
the critical function of DM is not to remove CLIP, but
rather to load peptide onto empty class II molecules which
would be susceptible to proteolysis. Hence, we propose
that the cooperative function between Ii and DM may be
to insure continuous groove occupancy of the class II mol-
ecule by peptide.
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